high grade glioma market
DelveInsight’s ‘High-grade Glioma (HGG) - Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the High-grade Glioma (HGG), historical and forecasted epidemiology as well as the High-grade Glioma (HGG) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The High-grade Glioma (HGG) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7 MM High-grade Glioma (HGG) market size from 2017–2030. The report also covers current High-grade Glioma (HGG) treatment practices/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
High-Grade Glioma Market Treatment Algorithm and Disease Understanding
The DelveInsight’s High-Grade Glioma market report gives a thorough understanding of the High-Grade Glioma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
High-Grade Glioma Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for High-Grade Glioma.
High-Grade Glioma Treatment
It covers the details of conventional and current medical therapies available in the High-Grade Glioma market for the treatment of the condition. It also provides High-Grade Glioma treatment algorithms and guidelines in the United States, Europe, and Japan.
High-Grade Glioma Epidemiology
The High-Grade Glioma epidemiology section provides insights about the historical and current High-Grade Glioma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the High-Grade Glioma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted High-Grade Glioma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017–2030.
Country Wise- High-Grade Glioma Epidemiology
The epidemiology segment also provides the High-Grade Glioma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
High-Grade Glioma Drug Chapters
The drug chapter segment of the High-Grade Glioma report encloses the detailed analysis of High-Grade Glioma marketed drugs and late-stage (Phase-III and Phase-II) High-Grade Glioma pipeline drugs. It also helps to understand the High-Grade Glioma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
High-Grade Glioma Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for High-Grade Glioma treatment.
High-Grade Glioma Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for High-Grade Glioma treatment.
High-Grade Glioma Market Outlook
The High-Grade Glioma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted High-Grade Glioma market trends by analyzing the impact of current High-Grade Glioma therapies on the market, High-Grade Glioma unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of High-Grade Glioma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated High-Grade Glioma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the High-Grade Glioma market in 7MM is expected to witness a major change in the study period 2017–2030.
Key Findings
This section includes a glimpse of the High-Grade Glioma market in 7MM.
The United States Market Outlook
This section provides the total High-Grade Glioma market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total High-Grade Glioma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total High-Grade Glioma market size and market size by therapies in Japan is also mentioned.
High-Grade Glioma Drugs Uptake
This section focuses on the rate of uptake of the potential High-Grade Glioma drugs recently launched in the High-Grade Glioma market or expected to get launched in the market during the study period 2017–2030. The analysis covers High-Grade Glioma market uptake by drugs; patient uptake by therapies; and sales of each drug.
High-Grade Glioma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of High-Grade Glioma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
High-Grade Glioma Pipeline Development Activities
The High-Grade Glioma report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses High-Grade Glioma companies involved in developing targeted therapeutics.
High-Grade Glioma Clinical Trials Development Activities
The High-Grade Glioma clinical trials report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for High-Grade Glioma emerging therapies.
Reimbursement Scenario in High-Grade Glioma
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views on High-Grade Glioma Market Trends and Dynamics
To keep up with current High-Grade Glioma market trends, we take KOLs and SMEs ' opinion working in the High-Grade Glioma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or High-Grade Glioma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the High-Grade Glioma unmet needs.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the High-grade Glioma (HGG) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
• The report covers the descriptive overview of High-grade Glioma (HGG), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the High-grade Glioma (HGG) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for High-grade Glioma (HGG) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of High-grade Glioma (HGG) market; historical and forecasted is included in the report, covering the 7 MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7 MM High-grade Glioma (HGG) market.
Report Highlights
• In the coming years, High-grade Glioma (HGG) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence High-grade Glioma (HGG) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• The report contains Gender-specific prevalence of HGG in the 7MM, wherein males are found to suffer more as compared to females.
• Report also covers Incident Population of Diffuse Midline Glioma, including both adult and pediatric population of HGG.
• DelveInsight has also estimated Incident Population of Diffuse Midline Glioma With H3K27 Mutation, including both adult and pediatric population of HGG. It was found that H3K27 mutation is more prevalent in adult DMG patients than in pediatric DMG patients.
• The most commonly used chemotherapeutic drug for treating HGG in the United States is temozolomide (Temodar/Temodal; TMZ). It is generally used in combination with radiation therapy.
• DelveInsight has found that there are certain upcoming therapies targeting specific mutations in HGG patient pool, such as Oncoceutics, MedImmune and DelMar Pharmaceuticals. Oncoceutics is developing ONC201, which is in phase II clinical trial for H3 K27M-mutant glioma and diffuse midline glioma. On the other hand, Durvalumab by MedImmune is also in its phase II trial for newly diagnosed unmethylated MGMT Glioblastoma.
High-grade Glioma (HGG) Report Insights
• Patient Population
• Therapeutic Approaches
• High-grade Glioma (HGG) Pipeline Analysis
• High-grade Glioma (HGG) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
High-grade Glioma (HGG) Report Key Strengths
• Eleven Years Forecast
• 7 MM Coverage
• High-grade Glioma (HGG) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
High-grade Glioma (HGG) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Questions
Market Insights:
• What was the High-grade Glioma (HGG) market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the High-grade Glioma (HGG) total market size as well as market size by therapies across the 7 MM during the forecast period (2020–2030)?
• What are the key findings pertaining to the market across the 7 MM and which country will have the largest High-grade Glioma (HGG) market size during the forecast period (2020–2030)?
• At what CAGR, the High-grade Glioma (HGG) market is expected to grow at the 7MM level during the forecast period (2020–2030)?
• What would be the High-grade Glioma (HGG) market outlook across the 7 MM during the forecast period (2020–2030)?
• What would be the High-grade Glioma (HGG) market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
• What is the disease risk, burden and unmet needs of High-grade Glioma (HGG)?
• What is the historical High-grade Glioma (HGG) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of High-grade Glioma (HGG) at the 7 MM level?
• What will be the growth opportunities across the 7 MM with respect to the patient population pertaining to High-grade Glioma (HGG)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of High-grade Glioma (HGG) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7 MM during the forecast period (2020–2030)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
• What are the current options for the treatment of High-grade Glioma (HGG) along with the approved therapy?
• What are the current treatment guidelines for the treatment of High-grade Glioma (HGG) in the US and Europe?
• What are the High-grade Glioma (HGG) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of High-grade Glioma (HGG)?
• How many therapies are developed by each company for the treatment of High-grade Glioma (HGG)?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of High-grade Glioma (HGG)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the High-grade Glioma (HGG) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for High-grade Glioma (HGG) and their status?
• What are the key designations that have been granted for the emerging therapies for High-grade Glioma (HGG)?
• What are the 7MM historical and forecasted market of High-grade Glioma (HGG)?
Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the High-grade Glioma (HGG).
• To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for High-grade Glioma (HGG) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for High-grade Glioma (HGG) market.
• To understand the future market competition in the High-grade Glioma (HGG) market.
